NASDAQ$ALHC

Alignment Healthcare Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Alignment Healthcare reported financial results for the fourth quarter and full year ended December 31, 2023.

Alignment Healthcare reported their Q4 and full year results, highlighting their confidence in the Medicare Advantage market and investments made to strengthen medical cost control and member experience.

  • The company is focused on thriving in the current Medicare Advantage market.
  • Investments have been made to improve medical cost visibility and control.
  • The company aims to bolster growth in 2024 and beyond.
  • Alignment Health offers more than 50 benefits-rich, value-driven Medicare Advantage plans.

Headline financials

Total Revenue

$465M

Previous: $362M+28.6%
EPS (adj)

-$0.25

Previous: -$0.31+19.4%
Health plan membership

119.2K

No prior period
Adjusted gross profit

$49.2M

No prior period
Adjusted EBITDA

-$19.7M

No prior period
Capital Expenditures

-$10.6M

No prior period
Net Income

-$47.2M

Previous: -$57M+17.2%
Operating Income

-$41.9M

Previous: -$52.1M+19.6%
Gross Profit

$47.6M

Previous: $35.8M+33.0%
Stock-Based Comp

-$51.2M

Previous: -$58.8M+13.0%

Revenue & EPS history

Alignment Healthcare · Revenue · Quarterly

$465M

Q4 2023+28.6%vs Q4 2022
Beat estimate in 15 of 15 quarters(100%)
ActualEstimate

Revenue by segment

Alignment Healthcare · $265M total across 2 segments · Q1 2021

  • Earned premiums
    $265M+18.0%
  • Other revenue
    $82K

Forward guidance

The company provided financial outlook for the first quarter ending March 31, 2024 and year ending December 31, 2024.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+1.8%

Avg return

Earnings day

+1.8%

Avg return

5 days after

+2.6%

Avg return

30 days after

57%

12 / 21 earnings

Positive

+27.0%

Q1 2024

Best reaction

-16.4%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.8%-15.7%-29.5%
Q4 2025-5.8%-7.5%-18.6%
Q3 2025-1.9%-0.4%+12.2%
Q1 2025-7.7%-7.5%-8.3%
Q4 2024+16.5%+17.4%+35.9%
Q3 2024+1.6%+12.2%+11.2%
Q2 2024+2.3%+4.9%+3.1%
Q1 2024+27.0%+31.6%+51.0%
Q4 2023-8.9%-9.2%-20.1%
Q3 2023-9.6%-7.2%+10.5%
Q2 2023+7.5%+10.5%-4.2%
Q1 2023+3.5%+11.3%-5.1%
Q4 2022-16.4%-20.9%-35.2%
Q3 2022-3.1%-3.3%-2.7%
Q2 2022+10.4%+4.3%-8.7%
Q1 2022-7.0%-18.8%+6.8%
Q4 2021+10.7%+8.0%+39.7%
Q3 2021+10.6%+6.1%-26.7%
Q2 2021-8.5%-4.8%-11.2%
Q1 2021+6.8%+13.3%+27.6%
Q4 2020+6.8%+13.3%+27.6%
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro